+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.

Age: 18Years - 130YearsAll GendersPhase 3
89 locations
R

Actively Recruiting

Researchers are evaluating luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East. This observational study aims to understand how luspatercept affects the need for blood transfusions and hemoglobin levels in real-world clinical settings. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have started luspatercept treatment within the past year. Participants receive luspatercept as prescribed according to the product label, with no experimental intervention assigned by the study. The study observes ongoing treatment and collects data retrospectively and prospectively, following participants for up to 144 weeks. Key measurements include changes in transfusion burden, pre-transfusion hemoglobin, and iron levels, among other clinical and healthcare utilization outcomes. During the study, participants provide signed consent and allow researchers to collect medical data relevant to their treatment with luspatercept. Researchers monitor transfusion visits, hemoglobin levels, treatment duration, dose adjustments, and other health indicators. The study includes comprehensive data collection on participants disease characteristics, comorbidities, and treatment history, aiming to provide a detailed understanding of luspatercepts use over nearly three years.

Age: 18Years +All Genders
13 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
A

Actively Recruiting

Researchers are evaluating EP0031 Lunbotinib, a next-generation selective RET inhibitor, in adults with advanced RET-altered non-small cell lung cancer NSCLC. This Phase III study aims to find the optimal dose and assess the safety, side effects, and effectiveness of EP0031 alone and in combination with standard chemotherapy. The study addresses a critical need as no approved RET-targeted treatments exist for patients whose cancer progresses after first-generation selective RET inhibitors SRIs. Participants receive EP0031 capsules once daily at the recommended dose alongside platinum-based doublet chemotherapy on Day 1 of each 21-day cycle, for up to four cycles. Following this, participants continue EP0031 with pemetrexed maintenance until disease progression, unacceptable side effects, or withdrawal. The study includes two groups treatment-naive patients and a now-closed cohort previously treated with a first-generation SRI. The Phase 1 dose escalation has completed, and the study is currently in Phase 2. During the trial, participants undergo regular assessments including tumor measurements using RECIST v1.1 criteria, safety and tolerability monitoring, and pharmacokinetic tests to measure drug levels in the body. Key outcomes include evaluating dose-limiting toxicities within the first 21 days and measuring overall response rates over 12 months. The study continues until March 2028, with ongoing observation of effects and side effects throughout treatment.

Age: 18Years +All GendersPhase 1Phase 2
52 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.

Age: 18Years - 65YearsAll GendersPhase 3
40 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the consistency of immune responses to three different batches of an investigational chickenpox vaccine called VNS vaccine in healthy children aged 12 to 15 months who have not had chickenpox or received a chickenpox vaccine before. The study also compares the safety and immune response of the VNS vaccine to an approved chickenpox vaccine known as Varivax. This Phase 3a study is sponsored by GlaxoSmithKline and aims to better understand the immune protection provided by these vaccines. Participants are randomly assigned to receive one dose of either one of the three investigational VNS vaccine lots or one of two lots of the marketed Varivax vaccine. Along with the chickenpox vaccine, they also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine HAV, and a pneumococcal conjugate vaccine PCV which could be PCV 13, Vaxneuvance, or PCV 20 depending on availability and country recommendations. All vaccines are given on Day 1 of the study. During the study, researchers monitor the participants immune responses by measuring antibodies against varicella zoster virus VZV and other vaccine components at Day 43. They also track safety by recording any side effects or adverse events from Day 1 to Day 181. The study includes diary reports by parents and regular clinical evaluations to assess immune response and safety outcomes. Participation involves a single vaccination visit and follow-up assessments over approximately six months.

Age: 12Months - 15MonthsAll GendersPhase 3
97 locations
R

Actively Recruiting

Researchers are collecting real-world data in the Gulf Cooperation Council GCC countries on patients with hormone receptor-positive HR-positive, HER2-low or HER2-ultralow metastatic breast cancer mBC who have previously been treated with endocrine therapy. The study evaluates patient characteristics, treatment patterns, survival outcomes, and the safety of Trastuzumab Deruxtecan T-DXd to help optimize treatments and improve outcomes for mBC patients in the region. This observational study follows patients who have started treatment with T-DXd as part of their routine care. Eligible participants include female patients aged 18 years or older with confirmed HR-positive metastatic breast cancer classified as HER2-low or HER2-ultralow, who have received at least one prior line of endocrine therapy but no chemotherapy in the metastatic setting. Patients are observed for up to 18 months to assess treatment patterns and safety. Participants will have their health information collected and monitored, including progression-free survival, time to next treatment, safety profiles, and baseline characteristics. Data is gathered through routine clinical visits without intervention from the study team. The study duration extends through March 2029, allowing for long-term observation of treatment outcomes and patient experiences.

Age: 18Years +FEMALE
9 locations
A

Actively Recruiting

Hepatocellular carcinoma HCC is a common and serious cancer worldwide, often linked to cirrhosis caused by hepatitis B or C viruses and steatotic liver disease. This research focuses on understanding the causes, patient and tumor characteristics, treatments, and outcomes of HCC in adults across various countries in the Middle East and North Africa region, where the disease burden is significant. Differences in healthcare resources and access in these countries affect diagnosis and treatment outcomes. The study collects and reviews existing medical records of adult patients diagnosed with HCC between 2015 and 2023 in the MENA region. It examines details such as patient demographics, tumor features, risk factors, and treatment methods used. This observational study uses secondary data collection without administering any new treatments or interventions. Participants will have their clinical information, laboratory tests, imaging results, and treatment histories analyzed from medical records. The research team will assess outcomes like overall survival and progression-free survival over an eight-year period. Data completeness and follow-up for at least six months are required for inclusion. The study aims to improve understanding of HCC management and outcomes in this region through detailed data review.

All AgesAll Genders
17 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether transferring a single genetically normal embryo during a natural menstrual cycle without routine luteal phase support LPS is not worse than transferring with LPS. This study focuses on women with regular ovulatory cycles who have at least one genetically tested embryo available, aiming to simplify treatment and improve participant comfort if the outcomes are similar. Participants are randomly assigned to one of two groups. Both groups will have intermittent ultrasounds and blood tests measuring hormone levels to monitor ovulation. In the group without LPS, embryo transfer is scheduled five days after ovulation without additional progesterone support. The group receiving LPS will be given vaginal progesterone starting on the day of embryo transfer and continuing until the pregnancy test, with support extended to seven weeks if pregnancy occurs. Throughout the study, participants will undergo multiple hormone measurements and ultrasounds to track follicular growth and hormone levels before and after embryo transfer. Pregnancy confirmation will occur via blood tests 10 days after transfer. The study will measure implantation rate, clinical pregnancy rate, live birth rate, and hormone levels at specific time points. Participant involvement includes frequent clinic visits for monitoring and blood draws over the course of the treatment cycle and early pregnancy period.

Age: 18Years - 40YearsFEMALEPhase 1
3 locations

1-10 of 12

1